ChartMill · Feb 24, 2026
Inogen Inc (NASDAQ:INGN) Stock Falls on Revenue Miss and Cautious 2026 Outlook
Inogen's narrower Q4 loss beat estimates, but a revenue miss and cautious 2026 outlook led to a sharp stock decline.
IN
NASDAQ · INGN
Inogen, Inc.
Healthcare · Medical - Devices
$5.94
Down-$0.17 (-2.86%)
Updated Oct 6, 2026, 11:18 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 190.85M
- P/E ratio
- -7.32
- Dividend yield
- 0.00%
- 52-week range
- $5.05 – $9.13
- Volume
- 348.97K
- Avg. volume
- 182.9K
Price performance · INGN
INGN price history
1M range · 0 trading sessions · Daily adjusted prices
INGN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest INGN news
The latest Smart Investors Daily articles mentioning INGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INGN research
Overview
Company profile and research snapshot.
Company profile
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 7, 2026 | Freedom Broker | Buy | — |
| Jun 16, 2025 | B. Riley Securities | Buy | — |
| May 22, 2025 | Needham | Buy | — |
| May 8, 2025 | Stifel | Hold | — |
| Apr 9, 2025 | Needham | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 24, 2026
Inogen, Inc. (INGN) Q4 2025 Earnings Call Transcript
Benzinga · Feb 24, 2026
Inogen Sees Q126 Sales in line with 1Q25
Inogen (NASDAQ:INGN) Sees Q126 Sales in line with 1Q25
Benzinga · Feb 24, 2026
CORRECTION: Inogen Sees FY2026 Sales $366.000M-$373.000M vs $385.250M Est.
Inogen (NASDAQ:INGN) sees FY2026 sales of $366.000 million-$373.000 million vs $385.250 million analyst estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
